IO Biotech, Inc. (IOBT)

NASDAQ: IOBT · IEX Real-Time Price · USD
2.80
+0.04 (1.27%)
At close: Dec 7, 2022 3:53 PM
2.85
+0.06 (1.97%)
After-hours: Dec 7, 2022 4:00 PM EST
1.27%
Market Cap 79.53M
Revenue (ttm) n/a
Net Income (ttm) -73.80M
Shares Out 28.82M
EPS (ttm) -7.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,522
Open 2.76
Previous Close 2.76
Day's Range 2.76 - 2.81
52-Week Range 2.15 - 11.14
Beta n/a
Analysts Buy
Price Target 12.75 (+356.2%)
Earnings Date Dec 16, 2022

About IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single... [Read more]

Industry Biotechnology
IPO Date Nov 5, 2021
Employees 32
Stock Exchange NASDAQ
Ticker Symbol IOBT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IOBT stock is "Buy." The 12-month stock price forecast is 12.75, which is an increase of 356.17% from the latest price.

Price Target
$12.75
(356.17% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Addition...

- Preclinical data showing the rationale for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 (TGF b 1) were presented in tw...

4 weeks ago - GlobeNewsWire

IO Biotech Announces Third Quarter Results for 2022

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

4 weeks ago - GlobeNewsWire

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combin...

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

1 month ago - GlobeNewsWire

IO Biotech to Participate in the Jefferies London Healthcare Conference

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

1 month ago - GlobeNewsWire

IO Biotech Announces Appointment of New Chief Financial Officer

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

1 month ago - GlobeNewsWire

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cance...

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

2 months ago - GlobeNewsWire

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pla...

3 months ago - GlobeNewsWire

IO Biotech Announces Second Quarter Results for 2022

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

3 months ago - GlobeNewsWire

IO Biotech to Participate in the 2022 BIO International Convention

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology plat...

6 months ago - GlobeNewsWire

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platf...

6 months ago - GlobeNewsWire

IO Biotech to Participate in the Jefferies Healthcare Conference

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platf...

6 months ago - GlobeNewsWire

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Li...

- First Patient Dosed in Proposed Registrational Trial in Melanoma - Multiple Sites to be Opened Across the United States, Australia, and Europe| - Trial Builds upon Phase 1 / 2 Results Recently Publish...

6 months ago - GlobeNewsWire

IO Biotech Announces First Quarter Results for 2022

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April -- -- Announced initiation and dosing of f...

6 months ago - GlobeNewsWire

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as Firs...

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Announces Year-End Results for 2021

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April-- -- Began Patient Recruitment for G...

8 months ago - GlobeNewsWire

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma from New Data Cut as of December 1, 2021

8 months ago - GlobeNewsWire

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pla...

9 months ago - GlobeNewsWire

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pla...

9 months ago - GlobeNewsWire

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody Publication of Phase 1/2 MM1636 Trial Resu...

11 months ago - GlobeNewsWire

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (p...

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for ...

1 year ago - GlobeNewsWire

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purcha...

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, inc...

1 year ago - GlobeNewsWire

IO Biotech, Inc. Announces Pricing of Initial Public Offering

WILMINGTON, Del., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public offering of 7,150,000 shares of its common stock at a...

1 year ago - GlobeNewsWire